On Gilead Sciences' 20th anniversary, analysts said the Bay Area biotech is in a strong position to remain independent and expand into new treatment areas. Gilead, the nation's dominant seller of HIV drugs, had sales of $3 billion in 2006, and some analysts are predicting substantial growth in revenue this year.

Related Summaries